Trial Profile
Phase I/II trial of Odiparcil in children with Mucopolysaccharidosis VI (MPS VI)
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2020
Price :
$35
*
At a glance
- Drugs Odiparcil (Primary)
- Indications Mucopolysaccharidosis VI
- Focus Adverse reactions
- Acronyms SAFE-KIDDS
- 10 Nov 2020 According to an Inventiva Pharma media release, this trial will not be initiated in the first half of 2021 as initially planned.
- 16 Sep 2020 According to an Inventiva Pharma media release, company decided to extend the duration of this trial evaluating odiparcil following a scientific advice meeting with the EMA in July; launch of the trial is expected in the first half of 2021
- 07 Feb 2020 According to an Inventiva Pharma media release, the launch of this study is planned for the end of the year.